Trial Profile

A Phase I First-in-Human multi-centre dose escalation study to assess the safety and tolerability of EBC-1013 Gel in participants with venous leg ulcers.

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 10 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

30 Jul 2026 According to QBiotics media release, company Advancing to the fourth cohort without dose-limiting toxicities or other safety concerns continues to build confidence in the safety profile of EBC-1013 and supports its development as a potential new treatment option for patients with difficult-to-heal wounds.
30 Jul 2026 According to QBiotics media release, company announce that the third cohort in its first in human Phase I wound healing clinical trial of EBC-1013 has successfully completed dosing and, following review by the trial's Safety Review and Dose Escalation Committee, has progressed to the fourth of five possible dose level cohorts.
30 Jul 2026 Status changed from planning to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com